title: Are dopamine D2 receptors out of control in psychosis?
abstract: It is known that schizophrenia patients are behaviorally supersensitive to dopamine-like drugs (amphetamine, methylphenidate). There is evidence for an increased release of dopamine, a slight increase of dopamine D2 receptors and an increase of dopamine D2High receptors in schizophrenia, all possibly explaining the clinical supersensitivity to dopamine. The elevation in apparent D2High receptors in vivo in schizophrenia matches the elevation in D2High receptors in many animal models of psychosis. The increased amounts of D2High receptors in psychotic-like behavior in animals may result from a loss of control of D2 by various factors. These factors include the rate of phosphorylation and desensitization of D2 receptors by kinases, the attachment of arrestin to D2 receptors, internalization of D2 receptors, the rate of receptor de-phosphorylation, formation of D2 receptor dimers, and GTP regulation by various GTPases. While at present there are no statistically significant associations of any of these controlling factors and their genes with schizophrenia, investigation of D2High receptors in schizophrenia will require a new radioligand in order to selectively label D2High receptors in vivo in patients. Finally, haloperidol reduces the number of D2High receptors that are elevated by amphetamine, indicating that this therapeutic effect may occur clinically.
authors.affiliation: Department of Pharmacology, University of Toronto, 260 Heath Street, West, unit 605, Toronto, Ontario M5P 3L6, Canada; Department of Psychiatry, University of Toronto, 260 Heath Street, West, unit 605, Toronto, Ontario, M5P 3L6, Canada. Electronic address: Philip.Seeman@utoronto.ca.
authors.forename: Philip
authors.initials: P
authors.lastname: Seeman
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D011485:Protein Binding / Q000502:physiology; D011618:Psychotic Disorders / Q000188:drug therapy / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000737:chemistry / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism
chemical_list: D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017448:Receptors, Dopamine D2; D004298:Dopamine
keywords: Caudate nucleus; Dopamine supersensitivity; Psychosis; Putamen; Schizophrenia; Striatum